BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32198297)

  • 1. Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study.
    Harding BN; Whitney BM; Nance RM; Crane HM; Burkholder G; Moore RD; Mathews WC; Eron JJ; Hunt PW; Volberding P; Rodriguez B; Mayer K; Saag MS; Kitahata MM; Heckbert SR; Delaney JAC
    BMJ Open; 2020 Mar; 10(3):e031487. PubMed ID: 32198297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight gain after antiretroviral therapy initiation in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
    Zhao X; Prajapati G; Tse J; Near AM; Kumar PN
    Curr Med Res Opin; 2023 Jul; 39(7):997-1006. PubMed ID: 37334707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
    Byonanebye DM; Polizzotto MN; Maltez F; Rauch A; Grabmeier-Pfistershammer K; Wit F; De Wit S; Castagna A; d'Arminio Monforte A; Mussini C; Wasmuth JC; Fontas E; Abela I; Sarcletti M; Bansi-Matharu L; Jaschinski N; Peters L; Hosein SR; Vannappagari V; Cohen C; Bissio E; Mocroft A; Law M; Ryom L; Petoumenos K;
    Lancet HIV; 2024 May; 11(5):e321-e332. PubMed ID: 38621392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States.
    Rebeiro PF; Emond B; Rossi C; Bookhart BK; Shah A; Caron-Lapointe G; Lafeuille MH; Donga P
    J Int AIDS Soc; 2023 Jun; 26(6):e26123. PubMed ID: 37306118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
    Tse J; Prajapati G; Zhao X; Near AM; Kumar PN
    Curr Med Res Opin; 2023 Sep; 39(9):1237-1246. PubMed ID: 37480288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia risk factors among people living with HIV across the United States in the current treatment era: a clinical cohort study.
    Harding BN; Whitney BM; Nance RM; Ruderman SA; Crane HM; Burkholder G; Moore RD; Mathews WC; Eron JJ; Hunt PW; Volberding P; Rodriguez B; Mayer KH; Saag MS; Kitahata MM; Heckbert SR; Delaney JAC
    BMC Infect Dis; 2020 Mar; 20(1):238. PubMed ID: 32197585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiometabolic Differences in People Living with HIV Receiving Integrase Strand Transfer Inhibitors Compared to Non-nucleoside Reverse Transcriptase Inhibitors: Implications for Current ART Strategies.
    Vos WAJW; Vadaq N; Matzaraki V; Otten T; Groenendijk AL; Blaauw MJT; van Eekeren LE; Brinkman K; de Mast Q; Riksen NP; Stalenhoef AFH; van Lunzen J; van der Ven AJAM; Blok WL; Stalenhoef JE
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
    Serrano-Villar S; Martínez-Sanz J; Ron R; Talavera-Rodríguez A; Fernández-Felix BM; Herrera S; Muriel A; Fanjul F; Portilla J; Muñoz J; Amador C; de Zárraga MA; Vivancos MJ; Moreno S;
    Lancet HIV; 2020 Aug; 7(8):e565-e573. PubMed ID: 32763219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
    Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
    Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database.
    Ruzicka DJ; Kuroishi N; Oshima N; Sakuma R; Naito T
    BMC Infect Dis; 2019 Jun; 19(1):505. PubMed ID: 31182050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in antiretroviral therapy prescription, durability and modification: new drugs, more changes, but less failure.
    Eaton EF; Tamhane A; Davy-Mendez T; Mathews WC; Moore RD; Saag MS; Mugavero MJ
    AIDS; 2018 Jan; 32(3):347-355. PubMed ID: 29194118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
    Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
    Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends and factors associated with modification or discontinuation of the initial antiretroviral regimen during the first year of treatment in the Turkish HIV-TR Cohort, 2011-2017.
    Korten V; Gökengin D; Eren G; Yıldırmak T; Gencer S; Eraksoy H; Inan D; Kaptan F; Dokuzoğuz B; Karaoğlan I; Willke A; Gönen M; Ergönül Ö;
    AIDS Res Ther; 2021 Jan; 18(1):4. PubMed ID: 33422112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens.
    Gianotti N; Muccini C; Galli L; Poli A; Spagnuolo V; Andolina A; Galizzi N; Ripa M; Messina E; Piatti PM; Lazzarin A; Castagna A
    J Med Virol; 2019 Nov; 91(11):1937-1943. PubMed ID: 31286527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage.
    Benson C; Emond B; Lefebvre P; Lafeuille MH; Côté-Sergent A; Tandon N; Chow W; Dunn K
    J Manag Care Spec Pharm; 2020 Feb; 26(2):129-141. PubMed ID: 31747358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study.
    Sangaré MN; Baril JG; de Pokomandy A; Klein M; Thomas R; Tremblay C; Pexos C; Durand M; Chawla S; Laporte L; Trottier H
    Clin Infect Dis; 2023 Jun; 76(11):1879-1888. PubMed ID: 36722329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy.
    Fabbiani M; Borghetti A; Squillace N; Colafigli M; Taramasso L; Lombardi A; Rossetti B; Ciccullo A; Colella E; Picarelli C; Berruti M; Latini A; Montagnani F; Sambo M; Di Biagio A; Gori A; Di Giambenedetto S; Bandera A
    J Acquir Immune Defic Syndr; 2021 Jan; 86(1):119-127. PubMed ID: 33306566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4/CD8 Ratio Recovery Among People Living With HIV Starting With First-Line Integrase Strand Transfer Inhibitors: A Prospective Regional Cohort Analysis.
    Han WM; Avihingsanon A; Rajasuriar R; Tanuma J; Mundhe S; Lee MP; Choi JY; Pujari S; Chan YJ; Somia A; Zhang F; Kumarasamy N; Tek Ng O; Gani Y; Chaiwarith R; Pham TN; Do CD; Ditangco R; Kiertiburanakul S; Khol V; Ross J; Jiamsakul A;
    J Acquir Immune Defic Syndr; 2023 Feb; 92(2):180-188. PubMed ID: 36625858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of antiretroviral therapy switch rate and switching pattern for people living with HIV from a national database in Japan.
    Naito T; Mori H; Fujibayashi K; Fukushima S; Yuda M; Fukui N; Tsukamoto S; Suzuki M; Goto-Hirano K; Kuwatsuru R
    Sci Rep; 2022 Feb; 12(1):1732. PubMed ID: 35110641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.